PRME
Prime Medicine, Inc.
Set alert
- YTD
- +36.02%
- 1 year
- +8.51%
- Open
- 5.03
- Prev close
- 5.24
- Mkt cap
- 856.10M
- Vol
- 6.57M
- Avg vol
- 3.97M
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.68
- High
- 5.20
- Forward P/E
- -3.96
- Beta
- 2.67
- Short ratio
- 5.85
- Inst. own
- 44.38%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.61
- 200-d avg
- 2.96
- 1y target
- 6.50
Key statistics
- Market cap
- 996.55M
- Enterprise value
- 828.19M
- Trailing P/E
- 0.00
- Forward P/E
- -3.96
- PEG ratio
- 0.00
- Price / sales
- 200.88
- Price / book
- 12.02
- EPS (TTM)
- -1.56
- Beta
- 2.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.96M
- Revenue growth
- 0.00%
- Free cash flow
- -103.37M
- Total cash
- 101.75M
- Total debt
- 119.74M
- Return on equity
- -154.81%
- Shares outstanding
- 178.27M
- Short % of float
- 18.46%
- 50-day average
- 4.61
- 200-day average
- 2.96
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 6.50
- Target (high)
- 10.00
- Strong buy1
- Buy6
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.24724.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2025 | Chardan Capital | main | Buy | Buy |
| May 27, 2025 | Citigroup | down | Buy | Neutral |
| May 20, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
| May 20, 2025 | JP Morgan | down | Overweight | Neutral |
| May 20, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| May 19, 2025 | Chardan Capital | main | Buy | Buy |
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- primemedicine.com
News
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
- Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
- Leading Indicators For The October Breakout Cycle
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
- Prime Medicine Gets FDA Green Light for Gene Editing Study
- Prime Medicine Gets FDA Green Light for Gene Editing Study
Your note
Sign in to keep a note on PRME — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS X LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 31, 2025 | 0 |
| BRUDNICK RICHARD | Officer | Purchase | May 19, 2025 | 20,000 |
| GOTTESDIENER KEITH MICHAEL | Chief Executive Officer | Stock Gift | Oct 7, 2024 | 0 |
| GV 2021 GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 31, 2025 | 0 |
| LEE ANN LOUISE | Officer | Purchase | May 20, 2025 | 100,000 |
| LIU DAVID R | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2025 | 20,240,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alphabet Inc. | 11.19% | 15,062,498 | 84.20M | Jun 29, 2025 |
| T. Rowe Price Investment Management, Inc. | 4.82% | 6,484,787 | 36.25M | Jun 29, 2025 |
| Blackrock Inc. | 3.33% | 4,485,828 | 25.08M | Jun 29, 2025 |
| FMR, LLC | 2.78% | 3,744,427 | 20.93M | Jun 29, 2025 |
| Vanguard Group Inc | 2.70% | 3,627,510 | 20.28M | Jun 29, 2025 |
| ARK Investment Management, LLC | 1.73% | 2,322,669 | 12.98M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.55% | 4,771,008 | 26.67M | Sep 29, 2025 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.65% | 3,569,787 | 19.96M | Jun 29, 2025 |
| -Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 1.58% | 2,124,252 | 11.87M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.56% | 2,095,110 | 11.71M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.06% | 1,429,992 | 7.99M | Aug 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.71% | 952,950 | 5.33M | Jun 29, 2025 |